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ABSTRACT
Computer Assisted Molecular Modeling of Thymidine Nucleoside
Analog Inhibitors of HIV-1 Reverse Transcriptase
by
Mark A. Fisher

An active analog approach to receptor mapping was used to identify the
three dimensional structural characteristics associated with a series of thymidine
nucleoside analog inhibitors of HIV-1 reverse transcriptase (RT) that may be
essential for their activity. Atomic substitutions at the 5 and 3' positions of
nucleoside analogs confer global structural and electrostatic changes that result in
either increased or diminished inhibitory activity. From a structural perspective,
the activity differences can be attributed to the presentation of select atoms in
three dimensional motifs that are common to all active compounds and absent or
distorted in inactive/poorly active compounds.
The identification of these characteristics will complement more direct
studies of the RT structure by providing a specific three dimensional orientation
for substrate and inhibitor molecules at their receptor site. They can also serve
as a three dimensional template for the screening of potentially active
compounds; thus, aiding in the development and identification of new, more
potent and selective inhibitor molecules.

The characteristics identified are

common to 15 thymidine nucleoside analog inhibitors of RT and have allowed
the inference of a three dimensional map of the HIV-1 RT receptor site.
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CHAPTER 1
BACKGROUND INFORMATION

1.1 Introduction
HIV-1 RT is an RNA dependent DNA polymerase class of enzyme that is
required for a productive viral infection. It is responsible for the conversion of a
virus' single stranded RNA genome to a double stranded proviral DNA form that
can be incorporated into the genetic information of a host cell. The catalysis of
such a critical step in the viral life cycle has mandated the use of inhibitors
specifically targeted at RT as anti-AIDS agents. Nucleoside analogs that lack the
3'-hydroxyl group (such as AZT, ddC, ddI, D4T, etc.) have been studied
extensively as potential anti-viral agents. The incorporation of these compounds
into a growing DNA chain results in chain termination due to their inability to
form a 3' ,5'-phosphodiester link with the incoming nucleotide. All nucleoside
analogs are assumed to act as competitive inhibitors of HIV-I RT following
intracellular conversion to their triphosphate (TP) form [1]. In many cases the
inhibitor binding constant (AZT-TP, KI=4.0nM) is stronger than that of the
natural substrate (dTTP, KI=500nM) [1]. For this reason, it is not fully
established whether chain termination, reversible competitive binding, or both
are primarily responsible for inhibitory activity. Although nucleoside analogs
preferentially interact with RT at the TP level, they are recognized by other
retroviral RTs and even cellular DNA polymerases. It is this nonspecific action
that contributes to their toxic side effects. In therapeutically effective compounds
the cytotoxic concentration is well above that required for antiviral activity.
The size, three dimensional shape, energetic, and electronic characteristics
of a molecule play an important role in its recognition and interactions with
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biological systems. It has been observed that nucleoside analogs that are
structurally closely related have very different levels of anti-IIIV activity
[1,2,3,4]. This has prompted a search for the identification of the exact three
dimensional structural characteristics that are responsible for the activity
differences amongst these compounds. The correlation of bioactivity with three
dimensional structural information will provide a molecular basis for the
recognition of these compounds that can be extrapolated to the de novo design of
more potent and specifically targeted RT inhibitors. I have limited this study to
nucleosides of the thymidine and uridine base motif because the skeletal
homology and competitive nature of these analogs suggest a common mode and
location of binding at RT, i.e. the same three dimensional structural
characteristics in each analog are recognized by the enzyme. With this
assumption, the identification of these common features becomes a matter of
comparing the structures of a number of inhibitors for common three
dimensional spatial arrangements. There is a high degree of flexibility in
nucleoside molecules which increases the potential for induced conformational
changes during the formation of protein-ligand complexes. The potential for
induced conformational changes in these compounds precludes conclusions
which are based upon the comparison of static X-ray crystallographic structures.
An approach which allows the comparison of a large number of compounds and
their sterically allowed molecular conformations for common spatial orientations
is most appropriate to this class of compound.

1.2 Historical Perspective
In the past, the computational demands of representing molecular structures in
the "real world" medium of three dimensions limited structure-based studies to
the use of hand held models. Recent advances in the development of high speed
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computer hardware and software algorithms, which support the real time
visualization and manipulation of molecular systems, have mandated the
development of computer based molecular modeling systems for the analysis of
three dimensional molecular characteristics. The use of molecular modeling
protocols, which are based upon the hypothesis of a common structural basis for
the activity of different compounds at a common receptor site, have been
successfully utilized to identify three-dimensional features that are important for
biological activity; and extrapolated to the design of potent new classes of
biologically active compounds. There are essentially two approaches to the
modeling of biomolecular systems each of which is dependent upon the amount
and type of experimental data that is available. The direct approach is based
upon experimental data associated directly with a macromolecular structure of
interest and generally requires an fairly well resolved X-ray crystallographic
structure to start. The indirect approach focuses upon experimental data related
to ligands and is used to infer the three dimensional structural features of a
macromolecules catalytic region based upon ligand complementarity.
An impressive example of the potential of the direct approach is the design
of two new influenza virus salidase inhibitors using computer assisted molecular
modeling protocols that improved upon the amount of structural and electronic
complementarity between the enzyme receptor site and a bound inhibitor [5].
The study was begun with an X-ray crystallographic structure of a known
inhibitor (2-deoxy-2,3-didehydro-D-N-acetyl-neuraminic acid), which resembles
the product of the sialidase-catalyzed reaction, complexed with the influenza
virus salidase enzyme. The salidase enzyme is a viral surface protein that assists
in the cellular release of newly synthesized virus and the movement of virus
through the mucus membrane of the respiratory tract. It is a glycohydrolase,
which cleaves the terminal a-ketosidically linked sialic acids of glycoproteins,
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glycolipids, and oligo-saccharides into sialic acid monomers. The X-ray
crystallographic sialidase-inhibitor complex provides the bound molecular
conformation of the inhibitor and its three dimensional position with respect to
the amino acid residues in the sialidase receptor site. Functional group
substitutions were made to the inhibitor which were energetically favored, i.e.
that reduced the energy content of the enzyme-ligand complex. The most
energetically favorable substitutions were used to design inhibitor analogs that
would theoretically form preferred complexes. Two new sialic acid analogs (4amino-2-deoxy-2,3-didehydro-D-N-acetylneuraminic acid and 4-guanidino-2deoxy-2,3-didehydro-D-N-acetylneuraminic acid) were designed using this
approach. These compounds were, subsequently, synthesized and assayed for
sialidase inhibitory activity, and found to be the most potent sialidase inhibitors
reported to date. Similar approaches have been used in the design of renin
inhibitors [6,7] and peptide inhibitors of the HIV-1 protease [8].
In the absence of experimental data related to macromolecular structure
(such as X-ray and biochemical analysis of structure and catalytic amino acid
residues), which would provide both the volume and location of the receptor site
along with the receptor bound orientation of substrate, an indirect modeling
approach is required. Marshall et al. has proposed an "active analog approach"
which is based upon the hypothesis that the enzymatic recognition of a series of
competitively active analogs is due to their presentation of common three
dimensional structural motifs [9]. This approach focuses on data associated with
ligands and the structural complementarity that should exist between them and
the receptors to which they bind. It has previously been used to identify the
homologous three dimensional atomic patterns present in a series of active
analogs, extrapolate them to the identification of new active analogs, and infer
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the three dimensional receptor features of the macromolecules to which they bind
[10,11]. The details of the approach are in Chapter 2.

1.3 Viral Life Cycle
The HIV-1 virus is member of the lentivirus retroviral subclass. This type of
virus maintains its genetic information as a single stranded (ss) (+) sense RNA
genome rather than double stranded (ds) DNA, as in eukaryotic cells. Unlike
other RNA viruses, the retroviral lifecycle includes an obligatory intermediate
period during which its genome is maintained as a provirus, integrated dsDNA.
This intermediate state is possible due to the process of reverse transcription,
which involves the production of a dsDNA copy of the viral genome based upon
a ssRNA template. This flow of information in the reverse direction of normal
transcription (rna → dna as opposed to dna → rna → protein) is catalyzed by a
unique class of DNA polymerases called reverse transcriptases, which can
conduct both RNA and DNA dependent DNA polymerization.
The HIV-1 virion consist of an inner core region which contains two
distinct ssRNA genomes as well as several enzymes required for early viral
replication events (such as reverse transcriptase, integrase, and protease). The
inner core is surrounded by an icosahedral shaped nucleocapsid shell and
glycoprotein envelope (see Figure 1). A productive HIV-1 infection requires a
high affinity binding reaction between the viral envelope glycoprotein, gp120,
and a cellular CD4 surface protein. The CD4 protein is present in low
concentrations on the surface of monocytes, macrophages, and antigen
presenting dendritic cells [12]; and in high concentrations on the surface of
immature T lymphocytes as well as mature T-helper lymphocytes. A structural
and electronic complementarity between the CD4 receptor of a cell and a virus'
gp120 protein is responsible for bringing a virus particle into close enough
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Figure 1: Schematic diagram of HIV virion [13].
proximity to a cell for a fusion reaction, mediated by the viral gp41
envelope glycoprotein, to facilitate viral entry (see Figure 2). In cells with an
abundance of CD4 surface protein, highly efficient cell occurs due to the
combined affects of CD4/gp120 binding and gp4l mediated fusion activity. In
cells with low levels of CD4 protein, the primary dependence upon fusion
activity results in less efficient viral entry. Following cell entry, a virus'
glycoprotein envelope is degraded by cellular lysozymes and the nucleocapsid
core moves toward the cell nucleus by a series of nuclear localization steps.
During the period between cell entry and nuclear localization the process of
reverse transcription occurs inside the viral core. This results in production of a
dsDNA copy of the ssRNA genome. Upon reaching the nucleus, the core is
degraded and a preintegration complex, which consist of the integrase protein
complexed with the viral dsDNA, enters the nucleus. The integrase protein
catalyzes the integration of viral dsDNA into the host cell genome, i.e.
formation of provirus.

7

Figure 2: Schematic diagram ofCD4:gp120 complementarity and the relationship
between gp120 and gp41.
Depending upon a number of host factors, the provirus will either enter a latent
phase, and become dormant, or a lytic phase in which progeny virus is actively
produced. Transcription of proviral DNA produces mRNA that can serve as
either progeny viral genomes or templates for translation into a single
polypeptide which is subsequently cleaved by the viral protease into individual
viral proteins. Genomic mRNA associates with viral proteins at positions along
the plasma membrane that have been altered to express viral envelope
glycoproteins, such as gp120 and gp41, at the cell's surface. The budding of new
virus occurs with the modified plasma membrane of the host cell serving as a
glycoprotein envelope for progeny virus.

1.3.1 Cell Death
The budding process itself is not sufficient to cause cell death or diminished life
span. It is the envelope glycoprotein mediated CD4/gp120 binding and fusion
reactions that are toxic events. Two types of cell death are facilitated by these
mechanisms. In cells presenting a high concentration of CD4 surface protein,
fusion reactions occur between the gp120 of budding virions and the CD4
protein on a cell's surface. This results is a series of auto-fusion reactions along
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the cell membrane which destroy its integrity and result in eventual death (see
Figure 3).
The other type of cell death is due to the fusion a single infected cell,
which presents viral envelope glycoproteins on its surface, with a number of
normal cells presenting CD4 surface proteins. A single infected T cell can fuse
with up to 500 uninfected CD4 presenting cells. This results in the formation of
large multinucleated cell syncytia which have short life spans (see Figure 4)
[12]. Evidence to substantiate these modes of cell death are observed as
decreased viral cytopathic effects in virus mutants that have defective fusion ,
gp41, domains or in cells with low CD4 surface concentrations; and a prolific
viral release from cells that have a low CD4 concentration without a loss of cell
viability.
There are a variety of proteins unique to and required by the HIV-1 virus
in order for it to establish a productive infection, such as the integrase, protease,
RT, and a number of structural proteins.

Figure 3: Auto-fusion reactions along cell membrane which result in destruction
of membrane integrity and cell death [12].
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Figure 4: Aggregation of single infected cell with several uninfected cells to
form multinuc_eated cell syncytia [12].
These proteins, for obvious reasons, are the chosen targets of antiviral therapy,
since they are not required for normal cellular functioning. Currently, all of the
proteins mentioned are under investigation as potential anti-AIDS agents. The
RT enzyme, which is one of the most unique and critical enzymes used by HIV1, has been the object of the most intense analysis.

1.4 Reverse Transcription
Reverse transcriptase is an RNA-dependent DNA polymerase class of enzyme
that is crucial for the replication of retroviruses. It is responsible for the
production of a dsDNA copy of a viruses (+)ssRNA genome (see Figure 5).

Figure 5: Input and output of reverse transcription.
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It also catalyzes the production of long terminal repeat (LTR) sequences at both
ends of the viral dsDNA, which is required for viral integration to the host
genome and acts as a transcriptional promoter/enhancer region. RT like other
DNA polymerases, synthesizes DNA in a 5' to 3' direction with the requirement
of a primer strand for initiation. Under normal conditions a primer is provided
by a primase enzyme which can add a short de novo RNA sequence to a single
DNA strand. However, this enzyme is not available in the inner core region of a
virus where reverse transcription takes place. A primer is provided by the
association of host tRNAiys, packaged in the virion during the preceding round
of viral assembly, with a primer binding site (PBS) on the viral genome [13].
The PBS is a sequence of 18 nucleotides in the viral genome that is
complementary to the 5' terminus of tRNA1ys. There are a number of
intragenomic regions that serve as cofactors for reverse transcription and
integration. In Figure 6 there is a schematic diagram of an RNA viral genome
and some of the regions that are involved in reverse transcription.

Figure 6: Schematic diagram of an RNA viral genome and the regions most
relevant for reverse transcription.
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Outline of reverse transcription (see Figure 7):
1. Host tRNA1ys binds to the PBS region of the viral RNA genome and a (-)
DNA strong stop copy of the 5'end of the viral genome is polymerized
by RT. The region of the viral genome just copied is degraded by the
ribonuclease H (RNase H).
2. The exposed 3' end of the strong stop (-)DNA base pairs with the other
(+) ssRNA genome packaged in the virion and dissociates from the
previous strand. The (-)DNA strand is extended to the PBS location on
the second genome, which contains a stop colon.
3. The majority of the second RNA genome is degraded by RNase H,
leaving small base paired RNA sequence in the vicinity of the 3' UTR.
This piece of RNA serves as a primer for polymerization of a (+) DNA
strong stop sequence and is, subsequently, degraded along with the
tRNA1ys by RNase H.
4. The PBS lip of the (+) DNA strong stop base pairs with the PBS region
of the (-) DNA strand and makes an intergenomic jump to the 3' end of
the (-) DNA strand. From this location, both strands are extended (5' to
3') to there full length and the resulting dsDNA contains LTRs at both
ends.

Figure 7: Graphical representation of reverse transcription events [12].
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1.5 Reverse Transcriptase Structure
HIV-1 RT is a heterodimer protein that consist of a 66 kilodalton (kD) and 51
kiloDalton subunit. The 6610 subunit (p66) contains both the polymerase (pol)
and RNase H domains. The heterodimer is a product of the proteolytic cleavage
of a p66-p66 homodimer, which removes the RNase H domain from one p66
subunit, producing a 51 kD subunit (p51). The pol domain is present in both
subunits but only catalytic in p66. A unique feature of the two subunits is that
the tertiary structure of the pol domain in the p66 and p51 subunits are
completely different, despite their identical primary and secondary features. The
most visible difference between the two subunits is the presence of a large cleft
in p66, which is large enough to accommodate an A- or B- form RNA-DNA
hybrid between the RNase and pol domains, analogous to that found in the
klenow fragment of E.coli DNA pol I [14].
The p66 subunit consist of five subdomains, four of which are in the pol
domain and one in the RNase H domain. An anatomical resemblance between
the four pol subdomains of p66 and a cupped hand led to their naming as fingers,
palm, thumb, and connection regions by Steitz et al. with the connection region
located between the pol and RNase H domains (see Figure 8). In Figure 9 there
is a picture of a recently solved X-ray crystallographic structure of RT
complexed with duplex DNA which was generously provided by Edward Arnold
[15].
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Figure 8: A cartoon structure of the p66 and p51 subunits of HIV-1 RT with
anatomical subdomains. Notice the predominant DNA binding cleft in the p66
subunit which is absent in p51 [14].
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Figure 9: Space filling rendition of recently solved X-ray crystal structure of
HIV-1 RT [15]. The colored portions are p66 (cyan), p51 (magenta), dsDNA
(yellow), and thymidine sustrate in vicinity of receptor site (white).

CHAPTER 2
METHODOLOGY

2.1 Active Analog Approach to Receptor Mapping
The active analog approach to receptor mapping is dependent upon the existence
of a common pharmacophore for a series of compounds demonstrating
competitive biological activity at the same protein. A pharmacophore is defined
as the atoms or groups whose three dimensional spatial orientation is required
for recognition by a given protein. It includes both the atoms and their three
dimensional positions with respect to one and other.
The active analog approach provides an indirect way of describing a
proteins receptor site based upon structural information associated with ligand
molecules. In the absence of well resolved crystallographic data related to a
protein of interest (as was the case with RT until recently[15]) this method
provides a means of inferring a protein's three dimensional receptor features.
The two premises upon which this approach is based are: 1) a common
pharmacophore exists for a series of compounds which demonstrate competitive
activity at the same receptor site and 2) the generation of all the sterically
allowed conformations a molecule can assume will produce at least one that is
bioactive, i.e. which presents a pharmacophore for which a receptor of
appropriate size and shape exists in the protein of interest. From this
perspective, the task of pharmacophore identification is that of generating the
sterically allowed conformations for a series of active compounds and then
analyzing them for common atomic spatial arrangements.
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Figure 11: Receptor map example. Enzyme excluded volume is the net volume
occupied by active analogs and, consequently, must be available at the receptor
site. Receptor essential volume is the net volume occupied by inactive analogs
which contains regions in conflict with enzyme volume at the receptor site.
Intersection volume is the portion of the receptor essential volume within the
receptor site, i.e.. not conflicting with enzyme volume at the receptor. The
receptor map is the cavity produced by subtracting the intersection volume from
the receptor essential volume. It represents the specific regions of volume excess
in the inactive compounds which conflicts with protein volume at the receptor. It
is, thus, an indirect map of the critical regions in the receptor site.

Subtraction of the intersection volume from the receptor essential volume
provides a three dimensional cavity which constitutes a receptor map (see Figure
11D). This is the net volume of the inactive analogs that is outside of the
receptor cavity and, consequently, which conflicts with protein volume at the
receptor site.
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2.1.2 Systematic Conformational Search
The systematic conformational search [22] is a tool for the investigation of the
conformational space available to a compound via the rotation of flexible bonds
(see Figure 12). It allows the definition of flexible bonds and their associated
torsion angles, which when varied, result in the generation of the sterically
allowed conformations that a compound can assume. The search algorithm
checks the van der Waals contacts amongst non-bonded atoms, while scanning
all possible combinations of torsional angle values. Only those conformations
without van der Waals overlap between non-bonded atoms are acceptable. The
search algorithm also provides a means of conformational discrimination based
upon the logical intersection, union, or difference between search data (i.e.
interatomic distances, torsional angles, conformational energy, etc.) from a
number of molecules. The combinatorial attributes of the systematic
conformation search allows the identification of the potentially pharmacophoric
patterns in a series of compounds. The pharmacophore provides a common
frame of reference for the orientation and superposition of active and inactive
analogs at the receptor site.

Figure 12: The search variables for the compounds under consideration.
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2.1.3 Method of Comparison
The most desirable method of comparison of potential pharmacophoric
patterns will allow the extrapolation of the pharmacophore to compounds from
different molecular classes, which may demonstrate common biological
activities. Interatomic distances were used as the metric for analysis and
comparison of the conformational data associated with each analog in this study
[9]. This method of comparison focuses upon the orientation of individual atoms
with respect to each other, independent of the overall molecular framework of a
compound. It allows the identification of pharmacophoric patterns that can be
applied to structurally diverse molecules, i.e. outside the nucleoside family,
which may demonstrate similar activity. Within this orientation space, a
pharmacophore consisting of a narrow range of interatomic distances between
specific atoms can be described in terms of an orientation map (OMAP) point,
which has a dimensionality that is equivalent to the quantity of interatomic
distances it contains. This reduces the comparison of three dimensional
molecular features to the comparison of distances between atom pairs, which can
be readily applied to structurally diverse compounds. The intersection of the
OMAP points from a set of active analog's provides the common and potentially
pharmacophoric atomic pattern(s) that are available (see Figure 13).
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Figure 13: OMAP example. Compound 1 was searched without constraints and
generated an OMAP point for every conformation (A-H). Compound 2 searched
without constraints will generate all of the given OMAP points (A,B,C,E,J,K,L,
and M), but with compound l's OMAP as a constraint only those common to
both (in bold). The searching of subsequent compounds with constraints results
in the identification of the OMAP points common to all in compound 4 (C and
E, in bold).
For example, an OMAP point is generated for each sterically allowed
conformation of a compound and contains interatomic distance data related to
predefined atom pairs. At the end of a systematic conformational search the
resulting OMAP of each compound contains a point for each conformation and,
thus, defines the entire set of sterically allowed spatial arrangements for the
designated atoms with respect to each other. Since by definition a
pharamcophore is a common spatial orientation of atoms in a series of active
analogs, at least one point in each compound's OMAP should be common to all
the analogs under consideration. The identification of the OMAP point(s) in each
compound that are common to the series provides a set of potentially
pharmacophoric patterns.
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The usefulness of this approach is in the fact that although a pair of atoms
may move throughout a common overall distance range in two compounds
(minimum: 6.0 A; maximum: 10.0 A) the movement is discontinuous in each;
and, the identification of common points inside this global range provides a
means of conformational discrimination, by eliminating conformations without
overlap in the segments that comprise an overall range (see Figure 14). An
intersection is identified using a search and constrain approach, in which OMAP
points are generated for a compound and used to constrain the conformations
generated for a subsequent compound to those common to both. Using this
approach, the last compound searched in a series will contain OMAP points
common to itself and all previously searched compounds, i.e. an intersection.

Figure 14: Example of distance range intersections as a means of identifying
commonalities amongst compounds. The overall ranges for both compounds are
identical, but when examined at a higher resolution one can see that there is
room for discrimination between the two.
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2.1.4 Search Resolution
The principal determinant of the quality of a systematic search is the resolution
of interatomic distance measurements. This is analogous to the maximum amount
of potential deviation that can occur between the pharmacophoric groups of two
different analogs. The Grid Size parameter of the systematic conformational
search defines the degree to which interatomic distances from different
compounds must agree in order to be considered common. In simplest terms, it
defines the increments with which interatomic distance measurement will be
taken. Consequently, the Grid Size parameter quantitatively regulates the amount
of pharmacophoric overlap between the selected atoms in different molecules.
For example, setting a grid size of 0.1 A results in the measurement of
interatomic distances at increments of 0.1 (i.e. 0.1, 0.2, 0.3, 0.4 A, etc).
Distances falling between grid points, such as 0.1 to 0.2 A or 0.2 to 0.3 A, are
in a relative dead space and will map to a the same midpoint distance, i.e.
0.15 A and 0.25 A, respectively. The grid size thus provides a means of defining
the level of accuracy with which interatomic distances will be measured. A grid
size of 0.1 A will map interatomic distances of 0.120, 0.144, and 0.151 A from
a molecule (A) and 0.149, and 0.168 A from a molecule (B) to a common
midpoint of 0.15 A, i.e. all would be considered identical. A more accurate
measurement would be made with a Grid Size of 0.01 A, which would only map
0.144 A from molecule (A) and 0.149 A from molecule (B) to the same
identical, at 0.145 A (see Figure 15). The grid size parameter provides a means
of defining the resolution with which the comparison of potential
pharmacophoric patterns will be made.
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Figure 15: Search resolution example. Comparison of 0.1 and 0.01 grid sizes.
The larger the grid size the greater the potential difference between interatomic
distances which map to the same OMAP point. A grid size of 0.1 will consider
interatomic distances within up to 0.1 A of, each other as identical (see top grid,
all distances are will be mapped to 0.15 A); whereas a grid size of 0.01 will
provide a more stringent range of 0.01 A for consideration as identical (see
_ower grid, only two distances within close proximity of each other are
considered identical).

CHAPTER 3
EXPERIMENTAL RESULTS AND DISCUSSION

3.1 Selection of Thymidine Nucleoside Analog Inhibitors
The compounds given in Table 1A were chosen based upon their selectivity
index (S.I.), which is the ratio of their cytotoxic concentration (CD50) to their
inhibitory (effective) concentration (EC50). Well designed anti-AIDS drugs will
maximize the numerator (CD50) and minimize the denominator (EC50). The
S.I. provides a numerical representation of the preference a compound has for
inhibition of viral enzymes over cellular enzymes. Although a S.I. is not a
direct measure of the affinity of a compound for RT, it provides an measure of a
its pharmacological effectiveness. A constant that is more indicative of the
relative affinity of an inhibitor for a particular protein is

From the equation it can be seen that the magnitude of K1 is representative
of the amount of enzyme and inhibitor that are in a complex form. KI is a
constant that has a propensity to vary greatly from one study to the next
depending upon the reaction conditions. For this reason, the results of studies
involving the calculation of KT are generally relative to the local conditions.
The relative values of KI for five of the compounds under consideration
were available from a single study [4]. There is apparently some correlation
between these and the respective EC50 and S.I. values of the given compounds.
In Table 1B the KI values for these compounds are arranged in increasing order,
i.e. decreasing affinity for RT. A relationship between KI, EC50 and Si is
most apparent when KI is compared to a modified S.I. which involves the ratio
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of S.I. to EC50. This is analogous to a selectivity index that places a greater
emphasis upon a compounds anti-viral activity (Modified S.I. = CD50 /
(ED50)2).

3.2 Software and Hardware
Molecular modeling studies were conducted on a Silicon Graphics Personal IRIS
workstation interfaced with a main frame HP-UX 9000 computer. The SYBYL
version 6.0 molecular modeling program from Tripos Associates [22], Inc. was
Table 1: Thymidine nucleoside active(+) and inactive(-) analogs with relevant
concentrations in PMB, MT-4 (-), and ATH8 (--) cells [2,16].
Compound
3'-Azido-2',3'-dideoxythymidine (AZT)
* 1.
3'-Azido-2',3'-dideoxyuridine (AzddU)
* 2.
3.
5-Chloro-3'-Fluoro-2',3'-dideoxythymidine (5C13FddU)
* 4.
5-ethyl-3'-Azido-2',3'-dideoxythymidine (SEtAzddU)
2',3'-dideoxythymidine (ddT)
* 5.
3'-Fluoro-2',3'-dide,oxyuridine (3FddU)
6.
5-Chloro-3'-Azido-2',3'-dideoxythymidine (5ClAzddU)
7.
8.
3'-Fluoro-2',3'-didemythymidine (3FddT)
9.
5-Bromo-3'-Azido-2',3'-dideoxythymidine (5BrAzddU)
5-Iodo-3'-Azido-2',3'-dideoxyurirdine (5IAzddU)
10.

ED50
0.004
0.2
0.38
1
0.2
0.04
0.72
0.001
1
1.1

* 11.
*12.
13.
14.

81
210
330
86

2'-Chloro-2',3'-dideoxyuridine (2ClddU)
2' ,3'-dideoxyuridine (ddU)
5-ethyl-3'-Fluoro-2',3'-dideoxyuridine (5Et-3FddU)
5-ethyl-3'-Iodo-2',3'-dideoxyuridine (5Et3IddU)

CD50
200
1000
535
1000
>125
16
213
0.197
> 100
>100
500
625
625
100

S.!.
50,000 (+)
5,000 (+)
1,408 (+)
1,000 (+)
>625 (+)
400 (+)
296 (+)
197 (+)
> 100 (+)
>91 (+)
6 (-)
3(-)
2 (-)
1.16 (-)

*: Crystal Structures; S.I.: Selectivity Index; ED50: 50 % Inhibitory Concentration (µM); CD50: 50 % Toxic
Concentration (µM)

Table 1A: Available KI values and modified S.I.
Compound
AZT
3FddT
AzddU
AzddEtU
3FddEtU

KI
0.006
0.007
0.016
0.12
2.3

ED50
0.004
0.001
0.2
1
330

S.I.
50,000
197
5,000
1,000
2

Modified S.I.
12,500,000
197,000
25,000
1,000
0.006
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used for molecular visualization and manipulation. The MAXIMIN2 molecular
mechanics program and MOPAC Semi-empirical Quantum Chemical program
[23] from the Quantum Chemical Program Exchange (QCPE # 455) at Indiana
University were the software packages used for geometry optimization of the
structures under consideration. Crystallographic data was obtained from the
Cambridge Crystallographic Database and generously provided by Patrick Van
Roey (Medical Foundation of Buffalo Inc.).

3.3 Energy Minimization
The success of any computer aided molecular modeling study is dependent upon
the accuracy of the starting geometries and method of calculating the relative
energies of the compounds under consideration. The most reliable starting
structure is one obtained from X-ray crystallographic data, which is analogous to
a snapshot of the given compound at some instant of time. In the event that such
data is not available, then software based construction of the compound is
required. Regardless of the source of the starting geometry, all the compounds
under consideration had their geometries optimized via a software based energy
minimizer at the beginning of the study. The optimization of the manually
generated structures eliminated bad electrostatic and/or van der Waals contacts
that were present in the structure.
X-ray crystallographic geometries are products of atomic interactions
within a matrix of similar molecules, which is usually not the medium of interest
and can produce structural characteristics unique to that environment. There is
also a of great deal of latitude with regard to the level of resolution that can be
achieved for a given molecular system. The X-ray crystal structure can be used
to evaluate the effectiveness of a molecular geometry optimizer. Significant
alteration of an X-ray crystallographic structure following optimization is
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generally indicative of a software geometry optimizer that is inadequate for the
given system. There are essentially two approaches to geometry optimization,
molecular mechanics and quantum mechanics, each of which has its own merits
and weaknesses.

3.3.1 Molecular Mechanics Method
The molecular mechanics method of geometry optimization is based upon the
experimentally based parameterization. It views a molecule as a collection of
points (atoms), connected by springs (bonds), with variable elasticities (force
constants). The process of parameterization involves the correlation of
experimentally observed data to potential energy functions which are stored in
molecular mechanics force fields. The value of a particular force field lies in the
variety and quality of its parameterization. A force field consist of a variety of
atom types for a given element. Each type of atom is designed to emulate
specific structural motifs (i.e. Carbon atom types: C(aromatic), C(sp3), C(sp2),
etc) based upon its experimentally derived potential energy functions.
With regard to geometry optimization, the molecular mechanics method
assumes a set of optimal bond lengths and angles based upon its parameters sets.
The energy of a molecule is defined according to the amount of deviation from
these "ideal" structural motifs. The summation of the effects of these deviations
over all bonds, valance angles, torsional angles, and non-bonded atomic
interactions represents the total molecular energy. A Descent Series Iterative
Method, which modifies the atomic coordinates of a structure from one iteration
to the next in the direction of decreasing energy, is the means by which
geometry optimization is achieved. This is generally a local energy minimum,
which is dependent upon the starting geometry of the compound. The major
problem with the molecular mechanics methods is that many of the force fields
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have been developed for use in specific modeling areas and, therefore, may not
be suited for a molecular system of interest.
The Tripos and AMBER force fields were available for use with the
MAXIMIN2 molecular mechanics method. The effects of geometry optimization
on each of the compounds under consideration using these two force fields were
analyzed. The most disturbing problem presented by this method was the lack of
appropriate parameters for nitrogen atoms in the azido configuration. This is a
linear structure that can be represented as the average of two resonance forms
(R-N=N=N and R-N-N≡N)[17]. In both force fields the only nitrogen atom
parameters available that allowed interactions with other nitrogens were sp3
hybridized and, consequently, resulted in tetrahedral azido geometries. The
nitrogen atom parameter which was sp hybridized (linear) lacked the parameters
necessary for interaction with other nitrogens. The only way to circumvent this
lack of azido parameters was to define the azido region of a molecule as an
aggregate. This abstains it from geometry optimization calculations and, thus,
retains the geometry of the crystal structure ( 171 0). Since the goal of this
study was to realize the effects that substitutions on the sugar and base moieties
have upon the overall nucleoside geometry, this method was not used.

3.3.2 Quantum Mechanics
The quantum mechanics approach differs from molecular mechanics in its
method of energy calculation. The energy in quantum mechanics calculations,
which is used to guide the geometry optimization of a compound, is derived
from approximate solutions to the Schrӧedinger equation:

Although, it can only be solved directly for a two particle system (hydrogen
atom: 1 proton + 1 electron), fairly accurate approximations to its solution for
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higher order systems have been achieved[18]. There are two approaches to this
goal, ab initio and semi-empirical.
The Hartree-Frock equations are based upon the ab initio approach and
approximates solutions for higher order systems by solving the Schroedinger
equation directly for 1-electron functions and extrapolating these solutions to
multi-electron systems (atoms

molecules). The solution for molecules is

approximated as the linear combination of the its' atomic orbitals, which are
functions of the 1-electron systems they contain.
The semi-empirical approach does not attempt to calculate solutions for all
the 1-electron functions of a molecule. Instead it considers the inner-core
electrons as a static region and focuses upon explicit solutions for valence
electrons only. It also ignores or replaces many of the integrals describing
electron interactions with experimentally determined parameters. Thus, it can be
viewed as almost a hybrid between quantum and molecular mechanics.
The advantage of the ab initio quantum mechanics method lies in the fact
that it makes no assignment of parameters based upon experimental data and,
therefore, can provide qualitative results related to molecular systems of
contemporary interest, which may not correlate to previously determined
experimental results. Its only drawback is in the requirement of a large amount
of computation to arrive at a solution. The computational demands, both volume
and time, have limited its application to systems of less than 20 atoms, unless a
supercomputing platform is available. The advantages and disadvantages of the
semi-empirical method are complementary to those of ab initio. In the
parameterization of some of its computational task it has reduced its accuracy
compared to ab initio, but can accomplish its solutions with increased speed and
decreased computational requirements. The speed and accuracy of the semiempirical method when compared to ab initio and molecular mechanics led to the
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selection of the Mopac program as the method of geometry optimization for this
study.
Mopac is a software package that contains four different semi-empirical
methods (PM3, MNDO, and AM1). The most contemporary method is PM3 and
the oldest is AM1. Each method was essentially designed to overcome
deficiencies in prior methods. I analyzed each method and found that in all three
the most striking inadequacies were an underestimation of sugar puckering and
production of a non-planar geometry in the base ring. In compounds with
definite 2' or 3' exo sugar conformations in crystal structures there was a
tendency to reduce the degree of exo puckering. And, the torsion angles in the
base ring of all compounds tended to deviate from values associated with
planarity (0° and 180°). To remedy the base planarity problem I utilized the
Mopac SYMMETRY option, which allows restriction of the range of variation
in a dihedral angle, valence angle, or bond length to that of another respective
angle or length in a molecule. Of the three methods available, AM1 produced
the least amount of reduced sugar puckering and distorted base planarity;
providing the optimized geometries that most closely resembled the crystal
structures. Thus, the geometry of each compound under consideration was
optimized using the AM1 method with SYMMETRY constraints.

3.4 Analysis of Sugar Puckering
In a preliminary study, it was found that limiting the sugar ring to the crystal
geometry resulted in very little structural homology amongst a set of only 5
thymidine nucleoside analogs [19]. This was a discouraging observation since the
most important attribute of a pharmacophore is its applicability to a large number
of active analogs. If at 5 compounds the amount of structural homology was
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slight, the prospects for extension of the given homology to a larger number of
compounds is not very good.
The fact that the geometry of a sugar ring is flexible and, therefore, could
be possibly be induced to undergo conformational changes upon complexing with
RT, prompted its inclusion as a conformational variable in this study (see Figure
12, bonds 1 to 4). To identify what values of angle rotation would be most
appropriate to this region of a nucleoside, the types of sugar puckering that were
produced by a number of different rotatable bond increments were analyzed.
Sugar puckering is defined as the deviation of an atom(s) from a plane defined
by three of atoms in the ring. The degree and type of puckering was analyzed by
the calculation of a psuedorotation phase angle (P). This is a single angle,
between 0 and 360°, which represents the cumulative effects that all of the
torsion angles in a five membered ring have upon puckering [20]. It gives a
qualitative idea of the net effect of changes in individual ring torsion angles upon
the overall ring conformation. This variable is important because the type of
puckering in the sugar ring has been suggested as a potential activity determinant
in these compounds [1]. A mathematical model was developed using the
Mathcad software package which accepts the individual torsion bond angles of a
large number of conformations and computes P based upon the Saenger equation
(see Appendix A)[20,21]:
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3.5 Method of Comparison: Interatomic Distances
The interatomic distances (atom pairs) in Figure 16 were selected because they
will most likely contribute to a pharmacophore for thymidine nucleoside analogs
at the RT receptor site. These interatomic distances were selected because they
involve heteroatom pairs, which may contribute to hydrogen bonding and
electrostatic interactions at the receptor site, and atoms that are common to all
the analogs, which allows correlation to the entire series of compounds. The
selected interatomic distances were not all inclusive because those without
variability between conformations (such as the distance between 04 and 02 of
the base) do not provide conformational discrimination. The distance between
the base center and O5' (interatomic distance H) was included because the
position of the base ring will effect potential hydrophobic interactions at the
receptor.

Figure 16: Interatomic distances (atom pairs) used as constraints in the
systematic conformational search.
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3.6 Systematic Conformational Search Results
The systematic conformational search was used to vary each compound along the
flexible bonds defined in Figure 12 and compare the interatomic distances
between the heteroatom pairs in Figure 15. All possible combinations of 1, 2, 3,
4, 5, 6, 7, and 8 interatomic distances were analyzed for simultaneous common
orientations in all the compounds under consideration (see Appendix B). A set of
seven interatomic distances (A,B,C,D,E,G, and H) with a single OMAP point as
their intersection was identified and as the highest amount of structural
homology and proposed as a potential pharmacophore (see Table 2, column A).
The OMAP point identified here was used to constrain the mobility of all the
compounds under consideration and identify the conformations in each that were
capable of presenting the proposed pharmacophore (see Table 2, column B). The
pharmacophore was applied to natural substrate (dT) and a completely inactive
substrate (uridine) for further validation. The fact that dT (natural substrate) is
capable of presenting the pharmacophore and uridine is not, supports the
proposed pattern.
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Table 2: Systematic Conformational Search OMAP Points
(A)
OMAP
Points
Compound
12,730
3' -Fluoro-2 ' ,3 ' -dideeoxythymidine (3FddT)
2,299
2' ,3'-dideoxythymidine (ddT)
99
5-ethyl-3'-Azido-2',3'-dideoxythymidine (5EtAzddU)
82
3 ' -Azido-2 ' ,3 '-dideoxyuridine (AzddU)
37
3 ' -Azido-2 ' ,3 '-dideoxythymidine (AZT)
31
5-Chloro-3 ' -Fluoro-2' ,3 ' -dideoxythymidine (5C13FddU)
19
3 '-Fluoro-2' ,3 ' -dideoxyuridine (3FddU)
19
5-Bromo-3'-Azido-2',3'-dideoxythymidine (5BrAzddU)
3
5-Chloro-3' -Azido-2' ,3' -dideoxythymidine (5ClAzddU)
3
5-Iodo-3' -Azido-2 ' ,3 ' -dideoxyurirdine (5IAzddU)
5-ethyl-3 ' -Fluoro-2 ' ,3 ' -dideoxyuridine (5Et-3FddU)
5-ethyl-3 '-lodo-2' ,3 '-dideoxyuridine (5Et3IddU)
2' ,3'-dideoxyuridine (ddU)
2'-Chloro-2',3'-dideoxyuridine (2C1ddU)

2
2

2'-deoxythymidine (dT: Natural Substrate)
Uridine (RNA)

1
0

1
1

(B)
Conformations
152
42
352
448
84
56
56
224
28
112
16
59
30
30
--

3.7 Bioactive Conformation Selection
With the identification and generation of a pharmacophore and the
pharmacophoric conformations, respectively, the next objective was to select a
bioactive conformation from amongst those presenting the pharmacophore. The
conformational data (torsion and P angles) associated with each compound were
analyzed for similarities. The conformations of individual compounds were
displayed superimposed along the pharmacophoric atoms (see Figure 17). This
provided a context for the type of variation in each compound which is
principally responsible for the generation of the pharmacophoric conformations.
It was found that in all compounds the base and sugar geometries were relatively
static and conformational variation was principally due to the rotation of bonds 7
(7 values, see Figure 12) and 8 (4 values), which together can generate up to 28
conformations. Analyzing the conformational data with the four sugar bonds
replaced by their associated P angle values, it was found that the number of
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conformations in many compounds were multiples of 28 in which the difference
between multiples was due to small changes in sugar puckering (P angle). In the
case of AZT, the 84 conformations generated were due to three different
pseudorotation phase angles which each repeated the same 28 conformations due
to rotation of bonds 7 and 8 (28 x 3 = 84 conformations). There was a
difference of ±2° between the three pseudorotation phase angles of AZT (176°,
175°, and 174°), resulting in three sets of structurally redundant conformations.
The production of redundant conformations due to small negligible changes in P
angle was a factor observed in all compounds with greater than 28
conformations. To reduce the amount of conformational redundancy, the
conformations in which the P angle was within ±5° of another conformation
were neglected. This reduced the number of conformations in each compound to
1/3 their original values.
With the number of conformations for each compound truncated and the
principal conformational variations due to rotatable bonds 7 and 8, energetics
were used to select the most appropriate positions of these bonds. The energy of
each of the remaining conformations was calculated using the AM1 method from
Mopac. In Figure 18 the energy with respect to bonds 7 and 8 reveals energy
troughs at ≈180° for rotatable bond 7 and ≈ 171° for rotatable bond 8 (where
applicable). The troughs observed for AZT were at similar positions in the other
compounds (see Appendix C for other compounds). The lowest energy
conformation of each compound was selected based upon these observations.
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Figure 17: All 84 conformations of AZT superimposed along the
pharmacophoric atoms.
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Figure 18: Graph of AM1 energy vs. rotatable bond 7 and 8 for AZT.
Horizontal axis is rotatable bond 7, vertical axis is energy, and color represents
position of rotatable bond 8. Notice the energy well at an angle of ° for
rotatable bond 7 and the lowest energy graph for rotatable bond 8 (azido:
171.3°-red).
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3.8 Receptor Mapping
With the bioactive conformation of each compound selected, the active and
inactive compounds were superimposed along the pharmacophore and a union of
the respective volumes was generated (see Figure 19). The intersection of these
two volumes, which represents the portion of the inactive compounds located
within the receptor site, was subtracted from the receptor essential (inactive)
volume to produce a receptor map (see Figure 20). This is the net volume
contribution of inactive analogs that is accessory to the enzyme excluded
volume. It represents regions occupied by protein volume at the receptor site.
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Figure 19: Active (left) and inactive (right) analogs superimposed along
pharmacophoric atoms (white).
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Figure 20: Union volume of active (magenta) and inactive (yellow) analogs
superimposed along pharmacophore, Intersection volume of active and inactive
analogs superimposed along pharmacophore (blue), and Receptor map (yellow).

CHAFFER 4
CONCLUSION

In this study, A method of molecular analysis that is independent of any
preconceived mechanistic notions was used to identify a unique pharmacophore
for thymidine nucleoside analogs and infer a three dimensional receptor map of
the receptor site of HIV-1 RT. The pharmacophore obtained in this is currently
being extended to a larger number of active and inactive RT inhibitors to further
validate it as the minimal structural requirement for thymidine nucleoside
analog-like activity at RT. Along with providing a frame of reference for the
orientation of these analogs at the RT receptor, It is hoped that this
pharmacophore will provide a template for the screening and identification of
new inhibitor molecules. A recently released adjunct to the SYBYL molecular
modeling program [22] allows the application of pharmacophoric data as a three
dimensional query constraint to the Cambridge Crystallographic Database, which
has structural information on > 60,000 compounds. This will allow the
identification compounds that can present the pharmacophoric pattern and, thus,
which may have inhibitory potential. The use of interatomic distances as the
method of pharmacophore definition allows the identification of compounds that
are capable of presenting the proposed pharmacophore outside of the thymidine
nucleoside molecular framework.
The receptor map provides an idea of the areas on nucleoside analogs that
are responsible for poor/in-activity at the RT receptor site. The map identified in
this study, which shows a great deal of volumetric conflict in the region of the
sugar ring, is in agreement with a number of contemporary opinions about the
important regions on these compounds. This receptor map will be used in
conjunction with biochemical and structural data associated with a recently
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solved crystal structure of HIV-1 RT to identify the specific region on its surface
with the greatest structural complementarity[15]. Each compound under
consideration will be positioned in their bioactive conformations at the proposed
receptor site and minimized as a protein-ligand complex. It is hoped that the
information obtained from the continuation of this study will provide useful
guidelines for the identification and synthesis of new inhibitors compounds and
facilitate a better understanding of the stucture-function relationships between
nucleoside analogs.

APPENDIX A
MATHCAD MODEL FOR THE CALCULATION OF THE
PSEUDOROTATION PHASE ANGLE (P)

43

44

For Educational Use Only

The Student Edition of MathCAD 2.0

MCAD model for calculation of Pseudorotation Phase Angle(P) in sugar ring
using individual torsional angles: V0(C4'-04'-C1/-C2'), V1(O4'-C1'-C2'-C3'),
V2(C1'-C2'-C3'-C4'), V3(C2'-C3'-C4'-04'), & V4(C3'-C4'-04'-C1'

Define Constants:

)

rad 1
deg ≡

-rad
180

Import Angle Data:

M := READPRN(filename)

i := rows(M)
x := 1,2 ..i

The following WRITE/READ equations convert the angle file from sybyl (an i x 4
matrix) to a usable mcad format:
<0>
WRITE(M0) := M
<1>
WRITE(M4) := M

MO := READ(M0)
M4 := READ(M4)

<2>

WRITE(M3) := M
<3>
WRITE(M2) := M

M3 := READ(M3)
M2 := READ(M2)
x

Generation of torsion angle in -40 to 40 degree range:
V0(x) := if M0 > 270, M0 - 359.9]
,M0 ]
x_
x
x
V2(x) := if-M2 > 270,-M2 - 359.9,M2 x
V3(x) := if-M3 > 270,M3 - 359.9],M3
x
M4 - 359.9 ,M4
V4(x) := if [M4 > 270,
[
x_
x
x
V1(x) := -(V0(x) + V2(x) + V3(x) + V4(x))
Y(x) := (V4(x) + V1(x)) - (V3(x) + VO(x))
X(x) := 2-V2(x)-1.5388

Y(x) P(x)
[

]

P(x) := atan
_X(x)_

P(x)
deg

P(x) := if(V2(x) < 0,(P(x) + 180),P(x))
P(x) := if(P(x) < 0,(P(x) + 360),P(x))
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The Student Edition of MathCAD 2.0
APPENDPRN(AZT8744P) := P(x)
i =

For Educational Use Only

APPENDIX B
SEARCH DATA FOR MUTIPLE PAIR CONSTRAINTS
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Data for Two Heteroatom Pair Constraints
Lead Pair
A

Pair2
B
C
D
E
F
G
H

OMAP Points
147
221
117
118
0
184
111

B

C
D
E
F
G
H

152
79
98
0
177
113

C

D
E
F

126
49
0
130
181

G
H
D

E
F

G
H
E

F

75
0
130
90

H

0
33
99

F

G
H

0
0

G

H

160

G
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Data for 3 Heteroatom Pair Constraints
Lead Pair
A

Pair2
B

Pair3
C
D
E
G
H

OMAP
Points
248
135
145
300
162

A

C

D
E
G
H

170
105
223
226

A

D

E
G
H

52
333
130

A

E

A

G

G
H
H

325
104
324

B

C

D
E
G
H

141
90
227
198

B

D

E
G
H

88
316
121

B

E

G
H

309
132

B
C

G
D

H
E
G
H

290
80
209
184

C

E

G
H

206
99

C

G

H

220

D

E

G
H

198
80

D

G

H

256

E

G

H

268
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Data for 4 Heteroatom Pair Constraints
Pair1
A

Pair2

Pair3

Pair4
E

G
H
D

E

G
H

G

50
146
131
104
109

G

H

236

D
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Data for 5 Heteroatom Pair Constraints
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Data for 6 Heteroatom Pair Constraints
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Data for 7 Heteroatom Pair Constraints
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APPENDIX C
ENERGY VS ROTATABLE BOND 7 AND 8
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